Access to Chemotherapy Services by Availability of Local and Visiting Oncologists

Marcia M. Ward, Fred Ullrich, Karen A. Matthews, Alexander M. Rush, Roger Tracy, Dean F. Bajorin, Michael A. Goldstein, Michael P. Kosty, Suanna S. Bruinooge, Amy Hanley, Charles F. LynchJournal of Oncology Practice 2014 · DOI

TL;DR

This study investigates how the geographic distribution of oncologists impacts cancer patients' access to chemotherapy in Iowa. It reveals that while the overall supply of oncologists in Iowa is favorable, their concentration in urban areas creates significant travel burdens for rural patients. The presence of visiting consulting clinics (VCCs) helps, but doesn't fully bridge the gap, highlighting the critical role of provider distribution in equitable cancer care access.

What Problem Does This Paper Address?

The paper addresses the growing concern of geographic disparities in healthcare access, specifically focusing on how the availability and location of oncologists affect cancer patients' ability to receive chemotherapy. While the total number of oncologists is important, their spatial distribution is a critical, yet often overlooked, factor. Studies have shown that limited access to specialized cancer care can lead to later diagnoses, suboptimal treatment, and increased mortality. This research aims to quantify the impact of local oncologist availability and the role of outreach services (VCCs) on patient travel times and treatment location within a statewide system.

Methods

The study utilized a comprehensive statewide cancer registry (Iowa Cancer Registry - ICR) to identify patients diagnosed with invasive cancers between 2004 and 2010 who received chemotherapy. This data was linked with the Iowa Physician Information System (IPIS), which tracks oncologists and their practice locations, including visiting consulting clinics (VCCs). Hospital Service Areas (HSAs) were used to define local markets. The researchers mapped patient residences, oncologist practices, and VCCs to these HSAs. Distances and travel times were calculated using GIS software and road network data. Statistical analyses, including bivariable and multivariable linear regression, were employed to identify factors influencing travel time.

Datasets

  • Iowa Cancer Registry (ICR): Provided data on 113,885 newly diagnosed invasive cancers in Iowa residents from 2004-2010, including information on diagnosis location, treatment type (including chemotherapy), and treatment location.
  • Iowa Physician Information System (IPIS): Provided data on oncologists' self-identified specialty, certification, and practice locations, including VCCs.
  • Hospital Service Areas (HSAs): Defined local healthcare markets, obtained from the Dartmouth Atlas of Health Care.
  • Rural-Urban Community Area (RUCA) codes: Used to classify patient residence as urban or rural.

Key Insights and Ideas

  • Provider Distribution is Key: The absolute number of oncologists isn't enough; their geographic distribution is paramount for equitable access. Even with a favorable overall supply, concentration in urban centers leaves rural populations underserved.
  • VCCs Offer Partial Solutions: Visiting consulting clinics (VCCs) do increase the rate of chemotherapy administration in rural communities and reduce travel times compared to having no local access. However, they don't fully replicate the access provided by a local oncologist.
  • Rural Patients Face Significant Travel Burdens: Patients in rural areas without local oncologists or VCCs experience substantially longer travel times for chemotherapy, highlighting a significant barrier to care.
  • Travel Time is Multifaceted: Driving time to chemotherapy is influenced by numerous factors, including cancer stage, age, sex, and residence location, underscoring the complexity of access.

Key Results

  • Of 35,745 patients receiving chemotherapy, 63.0% lived in an HSA with a local oncologist and traveled an average of 21 minutes.
  • In contrast, 29.3% lived in an HSA with a VCC but no local oncologist, traveling an average of 58 minutes.
  • 7.7% lived in an HSA with no oncology provider or VCC, traveling an average of 59 minutes.
  • The presence of a VCC increased the rate of chemotherapy administration in rural communities from 10% to 24%.
  • Patients in rural areas traveled approximately 3 times longer for chemotherapy than their urban counterparts.
  • While VCCs doubled local access, most patients in areas without a resident oncologist still traveled to urban sites for treatment.

Limitations and Future Work

  • Physician Coding: The study acknowledges that physicians are not exhaustively coded in ICR, meaning it's not definitively known if a patient saw a visiting oncologist, only if chemotherapy was administered at a facility with or without a local oncologist or VCC.
  • Confidentiality: Provider locations could not be divulged due to confidentiality safeguards.
  • Under-reporting: Potential under-reporting of chemotherapy and lack of detail on treatment type were limitations.
  • Patient Characteristics: Race/ethnicity and insurance status, known links to access issues, could not be examined due to data limitations.
  • Future Research: The authors suggest future research needs more specific data on factors influencing patient choices regarding available treatment options. Further investigation into the business models of VCCs and their impact on patient referral patterns is also warranted.

Summary updated

Abstract

Access to cancer care is dependent on the absolute number of providers, but it is also dependent on their geographic distribution.
BibTeX
@article{ward2014access,
  author = {Marcia M. Ward and Fred Ullrich and Karen A. Matthews and Alexander M. Rush and Roger Tracy and Dean F. Bajorin and Michael A. Goldstein and Michael P. Kosty and Suanna S. Bruinooge and Amy Hanley and Charles F. Lynch},
  title = {{Access to Chemotherapy Services by Availability of Local and Visiting Oncologists}},
  journal = {Journal of Oncology Practice},
  year = {2014},
  doi = {10.1200/jop.2013.001217},
}
Figure